FindTrial
Sign In

Prediction of spatial heterogeneity of tumor-infiltrating lymphocytes in pancreatic cancer based on pathomics and radiomics

Prediction of spatial heterogeneity of tumor-infiltrating lymphocytes in pancreatic cancer based on pathomics and radiomics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102194
Enrollment
Unknown
Registered
2025-05-09
Start date
2024-03-25
Completion date
Unknown
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Observation group :None

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Pancreatic cancer cohort 1. Surgery at our hospital; 2. Pathologic confirmation of pancreatic ductal adenocarcinoma; Neoadjuvant treatment cohorts 1. Surgery at our hospital; 2. Pathologic confirmation of pancreatic ductal adenocarcinoma; 3. Patients undergo neoadjuvant therapy before surgery.

Exclusion criteria

Exclusion criteria: Pancreatic Cancer Cohort 1.Patients lost to follow-up; 2.Quality issues with HE pathological slides; 3.Preoperative neoadjuvant therapy; 4.No preoperative enhanced CT images; 5.Patients have other malignant tumors; Neoadjuvant Therapy Cohort 1.Patients lost to follow-up; 2.Quality issues with HE pathological slides; 3.No preoperative enhanced CT images; 4.Patients have other malignant tumors.

Design outcomes

Primary

MeasureTime frame
Postoperative survival of patients;CT index;Image quantization and feature extraction;—

Countries

China

Contacts

Public ContactYun Bian

Shanghai Changhai Hospital

bianyun2012@foxmail.com+86 138 1635 7024

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026